Skip to Content
Merck
  • A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs.

A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs.

Journal of pharmacological sciences (2009-09-29)
Yoichi Ishitsuka, Hiroshi Moriuchi, Yoichiro Isohama, Hidehiro Tokunaga, Keita Hatamoto, Sumika Kurita, Mitsuru Irikura, Ken-ichi Iyama, Tetsumi Irie
ABSTRACT

This study examined the effect of ozagrel, a thromboxane A(2) synthase inhibitor, on the accumulation of leucocytes and chemokine mRNA expression in lungs experimentally injured using oleic acid (OA). OA injection into guinea pigs rapidly increased thromboxane A(2) generation and subsequently increased total protein concentration and the numbers of macrophages and neutrophils in bronchoalveolar lavage fluid and increased monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in the whole lung. Administration of ozagrel prevented these changes associated with OA injection. Ozagrel is a promising drug candidate for preventing acute lung injury.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ozagrel hydrochloride hydrate, ≥98% (HPLC), solid